Results 131 to 140 of about 76,287 (255)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli

Diabetes, Metabolic Syndrome and Obesity
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj  

Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review. [PDF]

BMC Musculoskelet Disord
Duru DO, Zhou AK, Lee DKR, Carroll PJ, Elmaraghy A.   +4 more
europepmc   +1 more source

AI‐Driven Synthesis in Medicinal Chemistry: Integrating Large Language Models, Robotic Automation, and Sustainability Metrics to Accelerate Drug Discovery

Medicinal Research Reviews, EarlyView.
ABSTRACT Artificial intelligence (AI) is transforming synthetic chemistry from task‐specific predictors into integrated platforms that unify retrosynthesis, reaction optimization, and closed‐loop robotic automation. This review highlights how AI‐assisted planning and robotic execution shorten cycle times, reduce step counts, and improve route ...
Amit Gangwal, Antonio Lavecchia
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation. [PDF]

J Am Chem Soc
Fallot LB, Anderson CA, Pinc JR, Stevenson A, Schleck MC, Hawryschuk E, Li OZ, Palchak JC, Toole JR, Kubiak Ii RW, Dear AJ, Michaels TCT, Limbocker R.   +12 more
europepmc   +1 more source

Weight Loss Intentionality and Strategies in Urinary Incontinence

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Urinary incontinence (UI)−including stress (SUI), urge (UUI), and mixed (MUI) subtypes−is associated with obesity, and weight loss is commonly recommended for intervention. However, the comparative effects of intentionality and weight loss strategies on UI severity remain poorly defined.
Eric S. Chai, Jonathan T. Ryan, Vismitha Naik, Nicolas Tapia‐Stoll, Katherine A. Amin, Ricardo Palmerola, Adam Williams, Raveen Syan   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis. [PDF]

Adv Ther
Panou T, Gouveri E, Popovic DS, Papanas N.   +3 more
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists as a Potential Mitochondrial Modulation Therapy for Hidradenitis Suppurativa. [PDF]

Acta Derm Venereol
Hosseini A, Von Gunten S, Hunger RE, Zouboulis CC, Seyed Jafari SM.   +4 more
europepmc   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity. [PDF]

Hypertens Res
Koyanagi Y, Iigaya K, Ikeda K, Onimaru H, Izumizaki M.   +4 more
europepmc   +1 more source